Little is known about the duration and protective capacity of the humoral immune response
to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In studies from Iceland1 …

We compared the performance of SARS-CoV-2 neutralising antibody testing between 12
European laboratories involved in convalescent plasma trials. Raw titres differed almost 100-…

Introduction The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring
COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim …

RNA viruses pose serious threats to human health. Their success relies on their capacity to
generate genetic variability and, consequently, on their adaptive potential. We describe a …

Background Several randomised clinical trials have studied convalescent plasma for
coronavirus disease 2019 (COVID-19) using different protocols, with different severe acute …

Influenza A virus segment 2 mRNA expresses three polypeptides: PB1, PB1-F2 and PB1-N40,
from AUGs 1, 4 and 5 respectively. Two short open reading frames (sORFs) initiated by …

Introduction Two large multicentre European hospital networks have estimated vaccine
effectiveness (VE) against COVID-19 since 2021. Aim We aimed to measure VE against PCR-…

Objectives This study aimed to assess the efficacy and safety of 300 mg camostat mesylate
three times daily in a fasted state to treat early phase COVID-19 in an ambulatory setting. …

After a pandemic wave in 2009 following their introduction in the human population, the
H1N1pdm09 viruses replaced the previously circulating, pre-pandemic H1N1 virus and, along …

The respiratory syncytial virus (RSV) represents the leading cause of viral lower respiratory
tract infections (LRTI) in children worldwide and is associated with significant morbidity and …